N-CPAPNasal Continuous Positive Airway Pressure
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The mean BMI (kg/[m.sup.2]) of group I (modified UPPP) was 29.21, of group II (classical UPPP) was 30.27, and group III (n-CPAP) was 31.60 with no statistically significant difference (P > 0.10).
The mean postoperative AHI/hour of group I (modified UPPP), group II (classical UPPP), and group III (n-CPAP) was 26.29 (S.D = 32.94, SEM = 10.98, p < 0.002), 46.93 (S.D = 8.14, SEM = 2.88, p < 0.001), and 0.00 (S.D = 31.75, SEM = 11.22, p < 0.001), respectively (Tables 3-7).
[3] The mainstay of therapy for OSA syndrome is n-CPAP therapy, which maintains a patent airway during sleep, thereby avoiding apnea.
The major complaints of the group III (n-CPAP) patients were poor compliance, abdominal bloating, nasal mucosal irritation, and dryness of mouth.
Arousal index, desaturation index, and all other variables measured except total sleep time showed improvements with n-CPAP, while AOP had no measurable effect on these variables, the researchers said.